Alteogen, Inc.

Alteogen, Inc.

Alteogen, Inc.

Overview
Date Founded

2008

Headquarters

62 Yuseong-daero 1628beon-gil,Yuseong-gu,Daejeon 34054

Type of Company

Public

Employees (Worldwide)

80

Industries

Biotechnology

Company Description

Alteogen, Inc. engages in the development, manufacture, and sale of biopharmaceuticals and anticancer drugs. Its products include technologies for anti-breast cancer drug and biosimilar, technology consulting, and other services. The company was founded on May 13, 2008 and is headquartered in Daejeon, South Korea.

Executives & Employees

Chairman & Chief Executive Officer

Director

Process Development Group

Biobetter Group

Board of Directors

Chairman & Chief Executive Officer at Alteogen, Inc.

Director at Alteogen, Inc.

Paths to Alteogen, Inc.
Potential Connections via
Relationship Science
You
Alteogen, Inc.
Recent Transactions
Details Hidden

Alteogen, Inc. issued KRW Ordinary Shares

Transaction Advisors
Underwriter

Advised onAlteogen, Inc. issued KRW Ordinary Shares

Clients

Government of South Korea provides news about Korea, Korean government policy, information on Korean history, Korean culture, and traveling in South Korea. It is composed of executive, legislative, and judiciary branch, independent organizations, and local governments.

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of pharmaceutical products and health foods. It operates through the following segments: Pharmaceuticals, Information Service, and Others. The Pharmaceuticals segment researches, develops, manufactures, and markets drugs, which are used in the fields of urology, dialysis, women's health, ophthalmology, endocrinology and metabolism. The Information Service segment offers information services to use in IT and capital investment. The Others segment includes merchandise sales and construction contractors. The company was founded on August 9, 1946 and is headquartered in Matsumoto, Japan.

Qilu Pharmaceutical Co., Ltd. manufactures and markets generic drugs. It offers services in the areas of oncology, infections, cerebrovascular and cardiovascular, psychological and neurological system, respiratory system and ophthalmological diseases. The company was founded in 1958 and is headquartered in Jinan, China.

Key Stats and Financials As of 2020
Market Capitalization
$3.06B
Total Enterprise Value
$4.25B
Earnings Per Share
$-0.02
Net Profit
$-838K
Total Equity
$118M
Total Debt
$12.3M
EBITDA
$1.71M
Revenue
$36.7M
Three Year Compounded Annual Growth Rate Of Revenue
51.9%
Debt TEV
0x
TEVNet Income
-5,065.37x
Enterprise Value EBITDAOperating
2,489.81x
Enterprise Value / Sales
115.76x
EBITDAMargin
4.65%
Investors
Details Hidden

Solidus Invest is an active manager which provides equity funding for seed and early stage capital requirement. The firm targets companies operating in industries such as biotechnology, commerce, food and agriculture.

Details Hidden

Magna Investment is an active manager which provides equity funding for seed and early stage capital requirements. It invests in a wide range of industries and sectors such as technology, content, and agriculture.

Suppliers
Merck KGaA Hospitals & Patient Services | Darmstadt, Germany

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Competitors
Celltrion, Inc. Biotechnology - Inchon, South Korea

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Biocon Ltd. Pharmaceuticals - Bangalore, India

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alteogen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alteogen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alteogen, Inc..